A2793 is an inhibitor of TRESK (IC50 value of 6.8 μM for mTRESK).

Mitiglinide calcium is a blood glucose-lowering drugs, stimulating insulin secretion by closing the ATP-sensitive K+ channels in pancreatic beta-cells.

Linopirdine 2HCl is a blocker of KV7 (KCNQ) voltage-gated potassium channels which blocks KV7.1 + 7.3 (KCNQ2 + 3) / M-currents (IC50 = 4 - 7 μM) and KV7.1 (KCNQ1) homomeric channels (IC50 = 8.9 μM), and is a putative cognition-enhancing drug.

Pinacidil monohydrate, an antihypertensive drug, is a potassium channel activator.

NS19504 is a selective activator of large-conductance Ca2+-activated potassium channels (BKCa, KCa1.1) with EC50 of 11 μM.

A2764 dihydrochloride is a selective inhibitor of TRESK (KCNK18) with an IC50 value of 11.8 μM. A2764 can inhibit TRESK in native cells, leading to cell depolarization and increased excitability.

NS3623 is an activator of both hERG and Kv4.3.

TAK-438, a potassium proton pump inhibitor, can reversibly inhibit H+/K+ ATPase with IC50 of 17 nM and does not affect Na+/K+ ATPase. It also controls gastric acid secretion.

Azimilide 2HCl, a class III antiarrhythmic compound, blocks the Kv7.1 and Kv11.1 patassium channels. It also inhibits Na+/Ca2+ exchanger in vitro.

AM 92016 is a K_V channel blocker.

JNJ 303 is a potent IKs blocker with an IC50 value of 64 nM. JNJ 303 does not have any effects on other cardiac channels at concentrations of 3.3 μM for INa, Ica, Ito, and IKr. JNJ 303 induces QT-prolongations and causes unprovoked torsades de pointes (TdP).

NS-1619 is a selective large conductance Ca2+-activated K+-channel activator.

Cloperastine fendizoate inhibits the hERG K+ currents in a concentration-dependent manner with an IC50 value of 27 nM.

Amifampridine is a quaternary ammonium compound that blocks presynaptic potassium channels, subsequently prolongs the action potential and increases presynaptic calcium concentrations, it was approved by the US FDA for the treatment of adults with LEMS.

SKA 31 is an activator of KCa3.1 and KCa2 channels with EC50 of 260, 2900, 2900 nM for KCa3.1, KCa2.1 and KCa2.2 respectively.

Azimilide is a class III antiarrhythmic compound, inhibits I(Ks) and I(Kr) in guinea-pig cardiac myocytes and I(Ks) (minK) channels expressed in Xenopus oocytes.

XE991 2HCl is a potent and selective blocker of KV7 (KCNQ) voltage-gated potassium channels which blocks KV7.2+7.3 (KCNQ2+3) / M-currents (IC50 = 0.6 - 0.98 μM) and KV7.1 (KCNQ1) homomeric channels (IC50 = 0.75 μM) but is less potent against KV7.1/minK channels (IC50 = 11.1 μM).

GAL-021 a new intravenous Potassium Channel KCa1.1 blocker.